We served as lead counsel representing the former owners of a multi-state retail pharmacy chain in connection with a Department of Justice (DOJ) investigation regarding alleged violations of the False Claims Act (FCA) resulting from inaccurate reporting of usual and customary pricing of generic drugs. The case resulted in declination by DOJ and dismissal of the underlying qui tam lawsuit after the filing of a motion to dismiss under the FCA’s first-to-file rule. Reported case: U.S. ex rel. Phillis v. Stephen L. LaFrance Holdings, 2018 WL 4839057 (N.D. Okla. Oct. 4, 2018).